Drug Approval | July 24, 2024
Zydus receives USFDA’s final approval for Valsartan Tablets
The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ - II, India
The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ - II, India
Reported profit after tax declined 19% year-on-year to Rs 76 crores
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
Rusan’s API facility in Ankleshwar is GMP approved by other stringent international agencies as well
The facility is a part of Lupin Manufacturing Solutions
The Unit has been issued GMP Certification from ANVISA-Brazil
Sacubitril and Valsartan combination is used to treat chronic heart failure in adults
Diroximel Fumarate Delayed-Release Capsules is indicated for the treatment of relapsing forms of multiple sclerosis
Laurus Labs receives EIR from USFDA for API facilities
This existing GMP compliant facility, located at Bharuch (Unit-1) with ongoing expansion part of the company's strategic capex initiative
Subscribe To Our Newsletter & Stay Updated
